Second Genome Presents Preclinical Data at Crohn’s & Colitis Foundation’s® IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455
November 18, 2021, BRISBANE, Calif.
Second Genome Presents Preclinical Data at SITC 2021 Demonstrating that a CXCR3-Positive Allosteric Modulator, SG-3-00802, Targets a Key Mechanism Required for Efficacious Immunotherapy
November 12, 2021, BRISBANE, Calif.
Second Genome Presents Preclinical Data Highlighting Potential Therapeutic Implications of Altered Gut Microbiome and Metabolites in Autism Spectrum Disorder Model and Parkinson’s Disease at The Society for Neuroscience Annual Meeting
November 11, 2021, BRISBANE, Calif.
Second Genome Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Demonstrating that a Novel Peptide, SG-3-0020, Upregulates Co-stimulatory and Checkpoint Pathways
October 7, 2021, BRISBANE, Calif.
Second Genome Announces Research Collaboration with Virginia Commonwealth University to Identify a Non-Invasive NASH Composite Biomarker
September 23, 2021, BRISBANE, Calif.
Second Genome Presents Preclinical Data at ESMO 2021 Demonstrating that a Novel Microbiome-Derived Peptide, SG-3-00802, Reverses Resistance to Anti-Programmed Death Protein-1 (PD-1) Therapy
September 16, 2021, BRISBANE, Calif.
Second Genome Announces Milestone Accomplished in Collaboration with Bayer, Demonstrating Broad Application of Company’s Machine Learning Platform to Identify Novel Proteins for the Development of Next-Generation Insect-Control Solutions
August 23, 2021, BRISBANE, Calif.
Second Genome Presents Preclinical Data Demonstrating the Effects of Microbial-Derived Metabolites in Autism Spectrum Disorder
August 10, 2021, BRISBANE, Calif.
